GGNNQ (Genocea Biosciences) Net Margin % : -5,917.78% (As of Mar. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Genocea Biosciences Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Genocea Biosciences's Net Income for the three months ended in Mar. 2022 was $-15.98 Mil. Genocea Biosciences's Revenue for the three months ended in Mar. 2022 was $0.27 Mil. Therefore, Genocea Biosciences's net margin for the quarter that ended in Mar. 2022 was -5,917.78%.

The historical rank and industry rank for Genocea Biosciences's Net Margin % or its related term are showing as below:

GGNNQ' s Net Margin % Range Over the Past 10 Years
Min: -21094.89 Med: -3216.63 Max: -676.13
Current: -1946.15

GGNNQ's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -140.3 vs GGNNQ: -1946.15

Genocea Biosciences Net Margin % Historical Data

The historical data trend for Genocea Biosciences's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences Net Margin % Chart

Genocea Biosciences Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Margin %

Get a 7-Day Free Trial

-3,216.63

-2,022.91

Genocea Biosciences Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Net Margin %	Get a 7-Day Free Trial															-	-	-220.72	-	-5,917.78

Competitive Comparison of Genocea Biosciences's Net Margin %

For the Biotechnology subindustry, Genocea Biosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genocea Biosciences's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genocea Biosciences's Net Margin % distribution charts can be found below:

* The bar in red indicates where Genocea Biosciences's Net Margin % falls into.

Genocea Biosciences Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Genocea Biosciences's Net Margin for the fiscal year that ended in Dec. 2021 is calculated as

Net Margin	=	Net Income (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-33.196	/	1.641
	=	-2,022.91 %

Genocea Biosciences's Net Margin for the quarter that ended in Mar. 2022 is calculated as

Net Margin	=	Net Income (Q: Mar. 2022 )	/	Revenue (Q: Mar. 2022 )
	=	-15.978	/	0.27
	=	-5,917.78 %

Genocea Biosciences (OTCPK:GGNNQ) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Genocea Biosciences Net Margin % Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genocea Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GGNNQ) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Acorn Park Drive, Cambridge, MA, USA, 02140

Website

https://www.genocea.com

Genocea Biosciences Inc is a USA-based biopharmaceutical company discovering and developing novel cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens , that drive pro-tumor immune responses.

Executives

John Lunger	director	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Jennifer Lyn Herron	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jacquelyn L Sumer	officer: CHIEF LEGAL & COMPLIANCE OFF	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Stapleton Raymond D Jr	officer: EVP PHARM SCI & MFG	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Gisela Schwab	director	6701 KAISER DRIVE, FREMONT CA 94555
Diantha Duvall	officer: CHIEF FINANCIAL OFFICER	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Girish N Aakalu	officer: CHIEF BUSINESS OFFICER	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Narinderjeet Singh	officer: SENIOR VP, PS&M	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Pamela Carroll	officer: SVP IMMUNO-ONCOLOGY	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Thomas Andrew Davis	officer: CHIEF MEDICAL OFFICER	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Derek M Meisner	officer: SENIOR VP AND GENERAL COUNSEL	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Michael Alfieri	officer: Principle Financial Officer	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Howard Mayer	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Cooper Ronald Harold Wilfred	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140